Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:9/9/2009

SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

  • The BioCentury NewsMakers in the Biotech Industry Conference on Wednesday, September 16, at 11:30 a.m. Eastern Time at the Millennium Broadway Hotel in New York
  • The UBS Global Life Sciences Conference on Wednesday, September 23, at 9:00 a.m. Eastern Time at the Grand Hyatt in New York

Dr. Hung will provide an overview of Medivation and its clinical development programs including dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
2. Medivation Announces Pricing of Public Offering
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
5. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
6. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Presents New Data on Dimebons Novel Mechanism of Action
8. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
9. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... SonaCare Medical, LLC reports the introduction of ... monitoring. The inaugural launch of this new technology occurred over the course of ... to a HIFU technical expert at SonaCare Medical headquarters. , Sonalink allows ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its ... Thailand and Singapore in the latest adipose and bone marrow therapies. , ...
(Date:2/9/2016)... , ... February 09, 2016 , ... With a presidential ... Wharton Health Care Business Conference will bring together over 500 top healthcare leaders for ... industry in transformation. The conference, organized by MBA students of the University of Pennsylvania’s ...
(Date:2/9/2016)... , ... February 08, 2016 , ... ... testing services, announced today the launch of its revamped and improved website. In ... language service solutions, the redesigned website will better communicate how the company designs ...
Breaking Biology Technology:
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
Breaking Biology News(10 mins):